GRIT
Trial Details: Glomerular Disease Registry
Populations: Glomerular Disease
PI: Dr Muh Geot Wong
Sponsor: The George Institute
PHOSPHATE
Trial Details: A Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis
Populations: Kidney Failure, Chronic Hyperphosphatemia
PI Dr Emma O’Lone
Sponsor: The University of Queensland, NHMRC
TRACK
Trial Details: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
Populations: Chronic Kidney Diseases, End-Stage Kidney Disease, Cardiovascular Disease
PI: Dr Muh Geot Wong
Sponsor: The George Institute
CARSK
Trial Details: Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates Populations
Populations: Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
PI: Dr Stella McGinn
Sponsor: University of British Columbia
RESOLVE
Trial Details: Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
Populations: Chronic Kidney Diseases, End-Stage Kidney Disease, Cardiovascular Disease
PI: Dr Yvonne Shen
Sponsor: The George Institute
REDUCCTION
Trial Details: Reducing the burden of dialysis Catheter Complications in patients with kidney disease: a National approach
Populations: End stage kidney disease, Haemodialysis Catheter complications
PI: Dr MuhGeot Wong
Sponsor: NHMRC
TIMELY
Trial Details: Treatment modalities for the InfirM ElderLY with end stage kidney disease: the TIMELY study
Populations: End Stage Renal Disease
PI: Dr Sarah Roxburgh
Sponsor: The George Institute, NHRMC Program Grant
CLARITY
Trial Details: Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease
Populations: End Stage Renal Disease, Cardiovascular disease
PI: Professor Carol Pollock
Sponsor: The George Institute
HaBIT 1
Trial Details: Incidence of De novo HLA Antibody formation after Transfusion with blood products in patients with end stage kidney disease who are planned for live donor kidney transplant: A prospective study
Populations: Live Donor transplant patients at participating hospitals who have a red cell transfusion scheduled.
PI: Dr Stella McGinn
Sponsor: Australian Red Cross Blood Service
TESTING
Trial Details: Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) (TESTING)
Populations: IgA Glomerulonephritis
PI: Dr Bruce Cooper
Sponsor: The George Institute
Teach PD
Trial Details: A pragmatic, registry-based, international, cluster-randomised controlled trial examining the use of TEACH-PD training modules for incident PD patients versus existing practices on the rate of PD-related infections
Populations: CKD, Peritoneal dialysis
PI: Dr Bruce Cooper
Sponsor: The University of Queensland acting through Australasian Kidney Trials Network (AKTN)
CONTEND
Trial Details: CONsumer views of Treatment options for Elderly patieNts with kiDney failure
Populations: CKD, End Stage Kidney Disease
PI: Dr Sarah Roxburgh
Sponsor: The George Institute, NHRMC Program Grant
PREVENA
Trial Details: Negative Pressure Wound Therapy (PREVENA) Versus Standard Dressings for Incision Management After Renal Transplant (IMPART)
Populations: Kidney Transplant, Vascular Surgery
PI: Dr Vikram Puttaswamy
Sponsor: Royal North Shore Hospital
ACHIEVE
Trial Details: Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
Populations: ESRF, Dialysis patient
PI: Dr Susan Wan
Sponsor: Hamilton Health Sciences
AlIGNI
Trial Details: A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
Populations: IgA Nephropathy
PI: Dr Muh Geot Wong
Sponsor: Chinook Therapeutics
AFFINITY
Trial Details: The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
Populations: IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
PI: Dr Muh Geot Wong
Sponsor: Chinook Therapeutics
FLOW
Trial Details: Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Populations: Diabetes Mellitus, Type 2
PI: Dr Muh Geot Wong
Sponsor: Novo Nordisk
DUPLEX
Trial Details: A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Populations: Focal Segmental Glomerulosclerosis
PI: Dr Muh Geot Wong
Sponsor: Retrophin, Inc.
PROTECT
Trial Details: A randomized, multicenter, double-blind, parallel-group, active-control study of the efficacy and safety of sparsentan for the treatment of immunoglobulin A nephropathy
Populations: Immunoglobulin A Nephropathy
PI: Dr Muh Geot Wong
Sponsor: Retrophin, Inc.
IONIS
Trial Details: An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy
Populations: Primary IgA Nephropathy
PI: Dr Muh Geot Wong
Sponsor: Ionis Pharmaceuticals, Inc.
ENVISION VIS649 (Previously called VISTERRA)
Trial Details: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy
Populations: IgA Disease
PI: Dr MuhGeot Wong
Sponsor: Visterra, Inc
